Tesis Labs, Personal Genome Diagnostics Ink Market Access Partnership

Original from Genomeweb 

Tesis Labs and Personal Genome Diagnostics said Tuesday that they are collaborating to develop new genomic tests for cancer patients that combine somatic and germline variant results, with the goal of advancing market access and accelerating adoption of their products.

In an email, PGDx said that the companies intend to combine Tesis' genomic data and reporting capabilities with somatic variant outputs from certain tissue tests to create a "comprehensive platform that provides patients with a streamlined experience … [combining] germline and somatic variants into a single clinical report."

The partnership also involves leveraging Tesis' patient outreach architecture to improve accessto genomic sequencing. "There is a growing body of evidence in the literature supporting the clinical value of testing all cancer patients universally for hereditary germline risk variants," PGDx wrote.

Financial terms of the arrangement were not disclosed.

Tesis offers targeted sequencing assays across a variety of diseases, including hereditary cancer risk testing, through labs in Colorado and Texas.

PGDx currently offers three pan-cancer NGS testing kits: the FDA-cleared Elio Tissue Complete, and the liquid biopsy assays Elio Plasma Complete and Elio Plasma Resolve.

"We are excited to partner with PGDx and leverage our aligned vision and collective expertise to enable new and creative clinical opportunities," Tesis CEO Ron King said in a statement.

"We look forward to working with Tesis Labs to further progress advancements in genomic insights and patient-centered oncology care," added PGDx CEO Megan Bailey.

Source: Tesis Labs, Personal Genome Diagnostics Ink Market Access Partnership | Genomeweb